Bausch Health Companies Target of Unusually High Options Trading (NYSE:BHC)

Bausch Health Companies Inc. (NYSE:BHCGet Rating) saw some unusual options trading on Friday. Stock traders purchased 68,278 call options on the stock. This is an increase of approximately 300% compared to the typical volume of 17,058 call options.

Wall Street Analyst Weigh In

BHC has been the subject of a number of recent analyst reports. Piper Sandler decreased their target price on shares of Bausch Health Companies from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Friday. Royal Bank of Canada increased their target price on shares of Bausch Health Companies from $4.50 to $8.00 and gave the company a “sector perform” rating in a research report on Thursday, September 1st. Truist Financial downgraded shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. Finally, JPMorgan Chase & Co. downgraded shares of Bausch Health Companies from an “overweight” rating to a “neutral” rating in a research report on Thursday, July 28th. Six research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.60.

Bausch Health Companies Price Performance

Bausch Health Companies stock opened at $7.40 on Friday. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of 61.67, a PEG ratio of 0.11 and a beta of 1.21. Bausch Health Companies has a 52-week low of $4.00 and a 52-week high of $29.58. The stock’s 50 day moving average price is $6.84 and its two-hundred day moving average price is $13.23. The company has a debt-to-equity ratio of 85.63, a quick ratio of 0.87 and a current ratio of 1.08.

Hedge Funds Weigh In On Bausch Health Companies

A number of institutional investors and hedge funds have recently modified their holdings of the business. Blueshift Asset Management LLC bought a new position in shares of Bausch Health Companies in the 1st quarter worth $464,000. Metis Global Partners LLC bought a new position in shares of Bausch Health Companies in the 1st quarter worth $254,000. Crescent Park Management L.P. bought a new position in shares of Bausch Health Companies in the 1st quarter worth $5,257,000. Guardian Capital Advisors LP lifted its holdings in shares of Bausch Health Companies by 154.6% in the 4th quarter. Guardian Capital Advisors LP now owns 36,650 shares of the company’s stock worth $992,000 after purchasing an additional 22,255 shares in the last quarter. Finally, Parkside Investments LLC lifted its holdings in shares of Bausch Health Companies by 9.6% in the 1st quarter. Parkside Investments LLC now owns 248,425 shares of the company’s stock worth $5,676,000 after purchasing an additional 21,850 shares in the last quarter. 70.07% of the stock is currently owned by institutional investors.

About Bausch Health Companies

(Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

Recommended Stories

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.